254 related articles for article (PubMed ID: 23651367)
1. Risks associated with the therapeutic use of fluoroquinolones.
Stahlmann R; Lode HM
Expert Opin Drug Saf; 2013 Jul; 12(4):497-505. PubMed ID: 23651367
[TBL] [Abstract][Full Text] [Related]
2. Safety considerations of fluoroquinolones in the elderly: an update.
Stahlmann R; Lode H
Drugs Aging; 2010 Mar; 27(3):193-209. PubMed ID: 20210367
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial safety: focus on fluoroquinolones.
Owens RC; Ambrose PG
Clin Infect Dis; 2005 Jul; 41 Suppl 2():S144-57. PubMed ID: 15942881
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolones in the elderly: safety considerations.
Stahlmann R; Lode H
Drugs Aging; 2003; 20(4):289-302. PubMed ID: 12641485
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of quinolones.
Stahlmann R; Lode H
Drugs; 1999; 58 Suppl 2():37-42. PubMed ID: 10553703
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin: new preparation. A me-too with more cardiac risks.
Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolones in children: poorly defined risk of joint damage.
Prescrire Int; 2004 Oct; 13(73):184-6. PubMed ID: 15499700
[TBL] [Abstract][Full Text] [Related]
8. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
Ball P; Mandell L; Patou G; Dankner W; Tillotson G
Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
[TBL] [Abstract][Full Text] [Related]
9. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
10. Safety issues and drug-drug interactions with commonly used quinolones.
Douros A; Grabowski K; Stahlmann R
Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):25-39. PubMed ID: 25423877
[TBL] [Abstract][Full Text] [Related]
11. The safety profile of the fluoroquinolones.
Bertino J; Fish D
Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507
[TBL] [Abstract][Full Text] [Related]
12. Safety concerns with fluoroquinolones.
Mehlhorn AJ; Brown DA
Ann Pharmacother; 2007 Nov; 41(11):1859-66. PubMed ID: 17911203
[TBL] [Abstract][Full Text] [Related]
13. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
Iannini PB
Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
[TBL] [Abstract][Full Text] [Related]
14. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Briasoulis A; Agarwal V; Pierce WJ
Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
[TBL] [Abstract][Full Text] [Related]
15. The fluoroquinolones.
Walker RC
Mayo Clin Proc; 1999 Oct; 74(10):1030-7. PubMed ID: 10918871
[TBL] [Abstract][Full Text] [Related]
16. Quinolones in the aged.
Nicolle LE
Drugs; 1999; 58 Suppl 2():49-51. PubMed ID: 10553705
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of fluoroquinolones.
Shimada J; Hori S
Prog Drug Res; 1992; 38():133-43. PubMed ID: 1609111
[TBL] [Abstract][Full Text] [Related]
18. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Adams DA; Riggs MM; Donskey CJ
Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
[TBL] [Abstract][Full Text] [Related]
19. Clinical toxicological aspects of fluoroquinolones.
Stahlmann R
Toxicol Lett; 2002 Feb; 127(1-3):269-77. PubMed ID: 12052667
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of quinolone antibiotics in the pediatric population.
Grady R
Pediatr Infect Dis J; 2003 Dec; 22(12):1128-32. PubMed ID: 14688586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
